An economic evaluation looking at the cost-effectiveness of the new medicine service (NMS) has found that the service increased patient medicine adherence by 10 per cent compared with normal practice, which translated into increased health gain at reduced overall cost.

The authors, from University College London and the Universities of Manchester and Nottingham, estimated that the NMS offers the NHS short-term savings of £75.4 million and long-term savings of £517.6 million.

They also suggest that consideration should be given to extending the NMS in other potentially beneficial therapeutic areas where there is significantly poor adherence.

Commenting on the findings of the study, Sue Sharpe, PSNC chief executive, said: “Pharmacists recognise that helping patients when they first receive a prescription for a new medicine can be pivotal to ensuring that they get the best possible outcomes. With the current pressures on the NHS it is vital to use community pharmacists to help support GPs and other parts of the health care system, using their expertise in medicines and the relationship they have with their patients.”

The Royal Pharmaceutical Society said the research provides a “resounding endorsement” of the service and has called for the NMS to be extended to other medicines, including in the area of mental health.

Recommended

Dovonex is switched from POM to P

Dovonex Psoriasis Ointment (calcipotriol 50mcg/g) has been reclassified as a P medicine, the MHRA has announced

Pharmacists key to reducing polypharmacy in over-70s

Medication reviews by clinical pharmacists will reduce polypharmacy in the over-70s, new research suggests

Popular

Health checks and diabetes prevention New Style

This module provides an update on both the NHS Health Check and NHS diabetes prevention programmes

CPD: Anxiety disorders in adults New Style

This module will help you understand the main types of anxiety disorder and their therapeutic management

Promoting long, healthy lives - the role of pharmacy

This NPA-accredited module, developed by CIG Healthcare Partnership on behalf of Merck Consumer Health, highlights risk ...